Nasal congestion

FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

Retrieved on: 
Monday, May 22, 2023

SILVER SPRING, Md., May 22, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use.

Key Points: 
  • This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use.
  • "The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products," said FDA Commissioner Robert M. Califf, M.D.
  • "On the heels of the FDA's recent approval of the first over-the-counter opioid reversal agent, the availability of nalmefene nasal spray places a new prescription opioid reversal option in the hands of communities, harm reduction groups and emergency responders."
  • If nalmefene is administered quickly, it can reverse the effects of opioid overdose, including respiratory depression, sedation and low blood pressure (i.e., hypotension).

Global Anti-snoring Devices Market 2023: Increased Awareness of the Negative Consequences of Snoring Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023

An increase in tobacco and alcohol consumption, as well as increased awareness of the negative consequences of snoring caused by these factors, are driving the market.

Key Points: 
  • An increase in tobacco and alcohol consumption, as well as increased awareness of the negative consequences of snoring caused by these factors, are driving the market.
  • Throughout the forecast period, technological advancements in the market will drive the global anti-snoring device market.
  • The growing patient preference for anti-snoring devices will drive demand for such devices, propelling the anti-snoring device market forward.
  • Furthermore, rising snoring awareness, increased disposable income, and advanced product development will drive demand for anti-snoring devices in the coming years.

Watch out for dangerous combinations of over-the-counter cold medicine and prescription drugs – two pharmacoepidemiology experts explain the risks

Retrieved on: 
Friday, April 21, 2023

When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.

Key Points: 
  • When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.
  • Nearly 70% of adults in the U.S. use over-the-counter medications as a first-line response for treating cold and flu symptoms.
  • We are a pharmacoepidemiologist and pharmacist team and we investigate adherence to medications and potential harms of medications associated with drug-drug interactions.
  • Another study estimated that every year, 26,735 people went to the emergency room for adverse events related to over-the-counter cold and cough medications.

The dangers of mixing medications

    • Pharmacists and physicians are typically knowledgeable about potential drug interactions, so it is very important for patients to ask their health care providers which over-the-counter medications are safe for them to use.
    • It is important to read the package ingredients of over-the-counter medications closely to avoid duplication of doses.
    • Cold medications are typically made up of multiple ingredients, including pain relievers, nasal decongestants and cough suppressants or expectorants.
    • Combining these decongestants with monoaminooxidase inhibitors or tricyclic antidepressants could lead to very high blood pressure and heart rhythm problems.

Each person responds to drugs differently

    • As we age, our bodies begin to lose the ability to efficiently clear drugs, which increases the risk of adverse events and unintentional overdoses.
    • Some drugs can be dangerous for people who have particular health conditions.
    • In addition, since these drugs are associated with increased blood pressure, patients with hypertension, hyperthyroidism or heart disease should be careful when using them, or avoid them altogether.

Alternatives for children

    • The Food and Drug Administration and the Centers for Disease Control and Prevention do not recommend giving cold medications to children under age 4.
    • Because of a variety of factors, young children have a higher risk of accidental overdose and adverse events that could lead to death.
    • Research has shown that honey can be helpful for reducing cold and flu symptoms in children older than age 1.

Pregnancy best practices

    • Acetaminophen is the doctor-recommended over-the-counter medication for management of pain and fever at any stage of pregnancy.
    • Any other pain relievers or anti-inflammatory medicine such as ibuprofen, ketoprofen, naproxen and aspirin should not be taken during pregnancy without a doctor’s approval.
    • For symptoms such as nasal congestion during pregnancy, a decongestant called oxymetazoline in its intranasal form is the drug of choice.

Astepro® Allergy Partners with Meghann Fahy to Help Allergy Sufferers Conquer Allergies, Love & Spontaneity Fast

Retrieved on: 
Thursday, March 30, 2023

Introducing Astepro® Allergy – the only long-lasting nasal spray that starts working in 30 minutes, so allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.

Key Points: 
  • Introducing Astepro® Allergy – the only long-lasting nasal spray that starts working in 30 minutes, so allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.
  • As a longtime allergy sufferer herself, Meghann Fahy understands the daily woes of powering through the runny nose or nasal congestion from allergies, but not anymore.
  • Astepro® and Meghann are working together to give allergy sufferers what they need to pursue passion this spring.
  • “About every 7 in 10 allergy sufferers say allergies make them feel less attractive or admit it’s affected their love life.

Bryn Pharma’s UTULY™ 13.2mg Intranasal Epinephrine Spray Provides Enhanced PK Profile (higher and more sustained) Compared to 0.3mg Epinephrine Autoinjector (EpiPen) in Subjects with and without Nasal Congestion

Retrieved on: 
Tuesday, March 28, 2023

The new research presented at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) annual meeting in Atlanta, Ga., showed that nasal congestion enhanced peak levels of epinephrine after intranasal administration of UTULY.

Key Points: 
  • The new research presented at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) annual meeting in Atlanta, Ga., showed that nasal congestion enhanced peak levels of epinephrine after intranasal administration of UTULY.
  • The poster, “The Effect of Nasal Congestion on the Bioavailability of Intranasally Administered Epinephrine in Healthy Adult Subjects with Seasonal Allergies,” can be found here .
  • UTULY is an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis.
  • These data show that UTULY is absorbed as fast as with an autoinjector, but also offers a higher and more sustained exposure of epinephrine.

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

Retrieved on: 
Tuesday, March 21, 2023

These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.

Key Points: 
  • These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.
  • NEUROMARK’s unique device and intelligent technology platform enable otolaryngologists to treat chronic rhinitis with precision and control, which in turn allows for an enhanced patient experience from treatment through recovery.
  • Total Nasal Symptom Score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.
  • “We’re encouraged by the three-month CLARITY data demonstrating the safety, efficacy and relief from chronic rhinitis symptoms that can be achieved with NEUROMARK,” said Neurent Medical CEO Brian Shields.

Allermi Secures $3.5M in Seed Funding to Meet Growing Demand for Customized Approach to Allergy Symptoms

Retrieved on: 
Thursday, March 16, 2023

Allermi , a direct-to-consumer telehealth service providing a customized approach to allergy relief, today announced a $3.5M seed round to continue its mission to deliver a personalized solution to allergy care.

Key Points: 
  • Allermi , a direct-to-consumer telehealth service providing a customized approach to allergy relief, today announced a $3.5M seed round to continue its mission to deliver a personalized solution to allergy care.
  • View the full release here: https://www.businesswire.com/news/home/20230316005335/en/
    World’s First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion.
  • Allermi launched in California last July with a $1.25M pre-seed round led by Lucas Venture Group and has been growing rapidly over 30% month-over-month.
  • The seed funding will be used to continue national expansion; build and scale business, marketing and product operations; and enlarge marketing channels to meet the growing demand.

EQS-News: Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray

Retrieved on: 
Thursday, March 16, 2023

Korneuburg, Austria, 14 March 2023 – Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), today announced positive results from its clinical study on the decongestant effect of the Sorbitol-containing Carragelose nasal spray.

Key Points: 
  • Korneuburg, Austria, 14 March 2023 – Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), today announced positive results from its clinical study on the decongestant effect of the Sorbitol-containing Carragelose nasal spray.
  • While Carragelose was shown to be an effective treatment of viral infections of the respiratory tract, Sorbitol exerts a decongestant effect.
  • The Carragelose and Sorbitol nasal spray was launched in 2018 and is currently marketed in 11 countries as a common cold product.
  • Based on the current clinical results, Marinomed plans to expand both the applications and target markets for the decongestant nasal spray.

Blueair Survey Reveals 45% of Americans Have Not Taken Steps to Improve Home Air Quality

Retrieved on: 
Wednesday, March 1, 2023

Poor indoor air quality continues to act as a silent threat, and according to a recent survey from Blueair, Americans remain at odds with the conditions inside their own residence.

Key Points: 
  • Poor indoor air quality continues to act as a silent threat, and according to a recent survey from Blueair, Americans remain at odds with the conditions inside their own residence.
  • In addition, 80% of Americans believe that clean indoor air results in a healthier home environment.
  • This awareness gap means many consumers are not taking important steps like changing HVAC filters and using air purifiers to improve their air quality.
  • Most Americans aren’t aware of the connection between skin health and air quality: Only 25% of survey respondents say they improved the air quality in their home to benefit their skin.

Respiray Announces Launch of Wear A+, an Innovative Solution for the 50+ Million Allergy Sufferers in the US

Retrieved on: 
Tuesday, January 31, 2023

TALLINN, Estonia, Jan. 31, 2023 /PRNewswire/ -- Respiray, the European tech company known for its innovative approach to health technology and improving air quality, announced its new groundbreaking wearable device that helps fight airborne allergies - Respiray Wear A+. It will be available for pre-order on Indiegogo starting today with a limited early bird special offer featured upon its initial launch.

Key Points: 
  • Ahead of the spring allergy season, production of Respiray Wear A+ will begin in February.
  • The first Indiegogo backers will get the products by the end of February just in time for allergy season.
  • Respiray Wear A+ offers a simple solution for people with airborne allergies.
  • After 2+ years, 117 prototypes, and extensive testing, we are proud to launch Respiray Wear A+."